Alector Inc(ALEC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.09 | Insider Own | 26.49% | Shs Outstand | 111.7M | Perf Week | -21.88% |
| Market Cap | 0.24B | Forward P/E | - | EPS next Y | 18.74% | Insider Trans | -0.77% | Shs Float | 82.1M | Perf Month | 1.67% |
| Enterprise Value | 0.10B | PEG | - | EPS next Q | -0.23 | Inst Own | 68% | Short Float | 7.19% | Perf Quarter | 39.8% |
| Income | -0.12B | P/S | 17.12 | EPS this Y | 38.03% | Inst Trans | 2.74% | Short Ratio | 5.74 | Perf Half Y | -8.41% |
| Sales | 0.01B | P/B | - | EPS next 5Y | 18.3% | ROA | -42.15% | Short Interest | 5.90M | Perf YTD | 36.22% |
| Book/sh | -0.09 | P/C | 1.37 | EPS past 3/5Y | 4.96% 10.72% | ROE | -385.11% | 52W High | -37.5% ($3.40) | Perf Year | -25.18% |
| Cash/sh | 1.55 | P/FCF | - | Sales past 3/5Y | -46% -0.05% | ROIC | -3160.47% | 52W Low | 94.95% ($1.09) | Perf 3Y | -62.72% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 6.27% | Gross Margin | 37.07% | Volatility(W/M) | 11.05% 10.53% | Perf 5Y | -90.66% |
| Dividend TTM | - | EV/Sales | 7.02 | Sales Y/Y TTM | -82.91% | Oper. Margin | -856.86% | ATR (14) | 0.22 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.26 | EPS Q/Q | 32.03% | Profit Margin | -850.13% | RSI (14) | 47.5 | Recom | 2.86 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.26 | Sales Q/Q | -57.84% | SMA20 | -8.36% ($2.31) | Beta | 0.6 | Target Price | $3.1 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/6 | SMA50 | 10.69% ($1.92) | Rel Volume | 3.67 | Prev Close | $2.27 |
| Employees | 103 | LT Debt/Eq | - | EPS/Sales Surpr. | 8.14% 93.78% | SMA200 | 9.59% ($1.93) | Avg Volume(3M) | 1.03M | Price | $2.12 |
| IPO | 2019/2/7 | Option/Short | Yes/Yes | Trades | 5217 | Volume | 3,779,894 | Change | -6.39% |
Company
ALEC is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Alector is a US clinical-stage biotech company focused on immuno-neurology. It targets neurodegenerative diseases such as frontotemporal dementia and Alzheimer's, developing a pipeline of genetically validated antibody, enzyme, and siRNA candidates. The company is primarily a drug developer advancing its lead programs through a collaboration with global pharmaceutical company GSK.
Over the past 1 year, roughly in the middle
38% below its 1-year high.
ALEC has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +38.0% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -62.7% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 68.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
QQQS 0.00%
IBRN 0.00%
FSEG 0.00%
IWC 0.00%
PRFZ 0.00%It ranks #4 in the industry
Based on market cap of $237M.
ALEC $237M PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is ALEC?
ALEC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ALEC?
The market cap of ALEC is approximately $237M, ranking 3,960 within its sector.
What is the 52-week high and low for ALEC?
ALEC has recorded a 52-week high of $3.40 and a low of $1.09.
